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ing’s syndrome. Transsphenoidal surgery (TSS) is the first choice of treatment. Predicting prog-
nosis after treatment can benefit further strategies of management, but currently there is no
convenient predictor. This study aims to investigate characteristic changes after treatment
and to identify potential prognostic predictors.
Methods: We retrospectively studied the records of CD patients presenting to the National
Taiwan University Hospital, Taipei, Taiwan between 1992 and 2011. They were categorized ac-
cording to treatment response. Clinical features and examination findings were compared be-
tween groups.
Results: Forty-one patients with CD were included. The follow-up time was 0.26e19.3 years.
The time interval between the onset of symptoms and diagnosis was 2.1e120.0 months. The
initial remission rate of CD after the first treatment was 82.9%. Mean body mass index (BMI)
was 27.4 kg/m2 before treatment and 26.0 kg/m2 3 months after treatment. The patients in
remission had a greater decrease in BMI after treatment and lower dehydroepiandrosteroneave no conflicts of interest relevant to this article.
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disease, Journal of the Formosan Mesulfate (DHEAS) levels before treatment, compared with the recurrent group (both p < 0.05).
Adrenocorticotropic hormone (ACTH) levels before treatment showed a significant positive
correlation with recurrent diseases (p < 0.05).
Conclusion: A larger decrease in BMI after treatment and lower DHEAS levels before treatment
were noted for the patients who stayed in CD remission. Higher ACTH levels before treatment
predicted a recurrence of CD. These are potentially simple and practical predictors of prog-
nosis.
Copyright ª 2016, Formosan Medical Association. Published by Elsevier Taiwan LLC. This is an
open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-
nc-nd/4.0/).Introduction
Cushing’s disease (CD) is the most common cause of
endogenous Cushing’s syndrome (CS).1 Transsphenoidal
surgery (TSS) is the first choice of treatment.1 Untreated CD
has been significantly associated with increased mortal-
ity;2,3 the 5-year survival rate is around 50% during the
natural course of the disease.2 Moreover, male sex, older
age at diagnosis, type 2 diabetes mellitus, depression, hy-
pertension, dyslipidemia, and obesity are all associated
with cardiovascular disease in CD.4,5 According to the
literature, the presence of cardiovascular disease, longer
duration of glucocorticoid (GC) exposure, older age at
diagnosis, and higher preoperative adrenocorticotropic
hormone (ACTH) levels are all associated with mortality in
CD.4,5 Patients who achieve remission after treatment have
a much better survival rate than those with persistent or
recurrent disease, and they do not have increased mortality
rates compared with the general population.6,7 Whether CD
is persistent, recurrent, or in remission affects prognosis;
therefore predicting the prognosis after treatment is
important, and will affect further strategies of
management.
In a recent large-scale study of 346 patients, none of the
variables studied [including age, sex, comorbidities at
diagnosis, immediate postoperative serum cortisol levels,
pituitary magnetic resonance imaging (MRI) findings, and
pathology] were predictors of CD recurrence.4 Another
study suggested that if tumors could be identified in both
preoperative images and pathologic specimens, remission
of CD was more likely to be achieved.8 In other words, if a
tumor cannot be identified and resected, it is more difficult
to achieve remission. Other studies have shown that very
low/undetectable postoperative serum cortisol levels are a
good predictor of long-term remission;8e10 only 7% of pa-
tients with very low postoperative serum cortisol levels had
recurrent CD.8e10 Low urinary free cortisol levels 6 weeks
after TSS treatment have also been associated with remis-
sion.8 In the above studies, serum and urine cortisol levels
should be obtained under conditions where there is no GC
supplementation. However, it is sometimes not feasible in
clinical practice because patients receive a GC supplement
when symptoms/signs of adrenal insufficiency develop
after surgery. That surgeons think the tumor has been
totally removed or the pituitary gland has been damaged so
much that adrenal insufficiency would develop also war-
rants GC supplementation. Other strategies that have beeno C-H, et al., Adrenocorticotropic
dical Association (2016), http://dproposed to predict long-term remission include measuring
cortisol levels after suppression with loperamide or dexa-
methasone, or after stimulation with corticotropin-
releasing hormone, desmopressin, or metyrapone.3,11e15
However, it is difficult to interpret the results of these
studies because of differences in the testing protocol, time
at which the tests were performed, and the dose of the GC
supplement before and during the tests.9 To our knowl-
edge, current predictors for CD recurrence after treatment
are not good enough. This study aims to investigate the
characteristic changes after CD treatment and to identify
other potential prognostic predictors, which should be
simple and practical for clinical usage.Methods
This study was approved by the Institutional Review Board
of the National Taiwan University Hospital (NTUH; Taipei,
Taiwan; protocol number 201305026RINC).
We retrospectively searched for all CD patients who
presented to NTUH between January 1992 and December
2011. Fifty-two patients were identified. In order to
comprehensively review all the details of medical records,
we selected the patients who received treatment for CD at
NTUH for further study (NZ 42). The patients who received
any treatment in other hospitals were excluded (N Z 10).
We also excluded the patient who received radiotherapy in
NTUH (N Z 1). The 41 patients who were enrolled for
analysis all received TSS as their first treatment for CD.
Diagnosis
CS was suspected at first presentation among all the pa-
tients included in the study because of the presence of
associated symptoms and signs. Diagnostic tests for CS
included the baseline serum ACTH and cortisol levels,
serum cortisol levels after 1 mg dexamethasone suppression
test (DST), and low-dose DST (0.5 mg dexamethasone every
6 hours for 48 hours, with post dexamethasone morning
serum cortisol levels > 2 mg/dL as the diagnostic criteria for
CS). Clinicians diagnosed CD based on the results of the
following tests: high baseline serum ACTH levels in patients
with CS, pituitary MRI, high dose DST (2 mg dexamethasone
every 6 hours for 48 hours, with post dexamethasone
morning serum cortisol levels < 50% of the baseline cortisol
level preferring the diagnosis of CD), and inferior petrosalhormone levels before treatment predict recurrence of Cushing’s
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mopressin. DST and inferior petrosal sinus sampling were
not performed in all patients. Patients with ACTH-
independent CS or ectopic CS were excluded from the
study.
Measuring outcomes
Initial remission after first treatment was defined according
to the following criteria: (1) improved symptoms and signs
of CS; (2) normal or lower than normal ACTH and cortisol
levels within 3 months after treatment (or need for
continued GC supplementation for general well-being
within 3 months after treatment); and (3) no visible pitui-
tary tumor on the follow-up MRI (if data were available).
Patients who failed to meet any of the above criteria were
classified as having persistent CD and were assigned to the
persistent group. Patients were classified as having recur-
rent CD and were assigned to the recurrent group if they
achieved initial remission but subsequently developed CD
recurrence during follow-up. The patients who achieved
initial remission and had no recurrence during follow-up
were assigned to the remission group.
Long-term remission was defined by the following
criteria: (1) normal or lower than normal ACTH and cortisol
levels without GC supplementation at the latest follow-up
(or need for continued GC supplementation for general
well-being); (2) no evidence of pituitary tumors on most
recent MRI; and (3) follow-up for more than 3 years after
initial treatment.
Statistical analysis
Results are expressed as mean  standard deviation or
median (range). To analyze changes in characteristics
before and after treatment, a paired samples t test was
used for parametric data, while the Wilcoxon signed-rank
test was employed for nonparametric data.
Data on patients with persistent CD were compared with
the remission group. One-way analysis of variance was used
for univariate analysis, and a logistic regression model was
used for the multivariate analysis. The Pearson Chi-square
test and Fisher’s exact test were used to analyze categor-
ical variables for parametric and nonparametric data,
respectively. The Cox proportional hazards model was used
for time-to-event analyses and to determine harzard ratios
of variables under study to predict recurrent CD. Stata/SE
11 for Windows (StataCorp LP, College Station, TX, USA)
was used for statistical analysis. A p value  0.05 was
considered statistically significant.
Results
Clinical features and signs
Patients’ characteristics are listed in Table 1. The median
age at diagnosis was 36 years (range, 5e66 years). There
were 36 (87.8%) female patients. Time between the onset
of symptoms and diagnosis was 2.1e120.0 months (median,
18.4 months). The most common presentations were asPlease cite this article in press as: Kuo C-H, et al., Adrenocorticotropic
disease, Journal of the Formosan Medical Association (2016), http://dfollows: moon face (80.5%), weight gain (65.9%), obesity
(63.4%), menstrual disturbance (47.2% of women), acne
(46.3%), buffalo hump (41.5%), thin skin or easy bruising
(34.2%), purple striae over the abdomen or thighs (29.3%),
increased hair on the face, torso, or extremities (29.3%),
plethora (24.4%), edema (22.0%), mood disorder or
insomnia (22.0%), proximal muscle weakness (17.1%),
lumbago (14.6%), hyperpigmentation (14.6%), headache
(9.8%), blurred vision or visual field defects (9.8%), and hair
loss (7.3%). Common comorbidities included dyslipidemia
(58.5%), hypertension (56.1%), hyperglycemia (39.0%),
osteopenia or osteoporosis (22.0%), fracture (14.6%), and
urolithiasis (12.2%).
According to the definition of the Health Promotion
Administration in Taiwan, patients were categorized as
underweight [body mass index (BMI) < 18.5 kg/m2], normal
weight (BMI 18.5e23.9 kg/m2), overweight (BMI
24.0e26.9 kg/m2), or obese (BMI  27 kg/m2).16 Before
treatment, more than half of the patients were overweight
(14.6%) or obese (48.8%). Thirty-two percent of patients
had higher ACTH levels than normal (normal, 10e65 pg/
mL). All patients had baseline ACTH levels higher than
10 pg/mL. Ninety-three percent of patients had lost their
diurnal rhythm of serum cortisol.
Tumor diameter was 2e17 mm with a median diameter
of 5 mm. More than 90% of tumors showed lateralization on
MRI (right side, 46.3%; left side, 46.3%).
Complications
Complications are shown in Table 1. Patients with symp-
toms, signs, and laboratory results indicating hypothyroid-
ism or adrenal insufficiency, as well as those who needed to
continue thyroxin or GC supplementation due to pituitary-
directed therapy were categorized as having hypopituita-
rism. Patients with symptoms, signs, laboratory results, or
imaging results that indicated diabetes insipidus (DI) and
those who needed to continue desmopressin supplemen-
tation were classified as having DI. The most common
complications after TSS were hypopituitarism, DI, and ce-
rebral spinal fluid leakage. Less common complications
included infection of the central nervous system or the
surgical wound, hemorrhage of the residual tumor or the
wound, and seizure.
Outcome
The follow-up periods for patients were 0.26e19.3 years
(median, 5.1 years). The initial remission rate after the first
treatment was 82.9% (Table 1). Sixty-nine percent of pa-
tients went into long-term remission after all the treat-
ments they received.
Changes of characteristics after initial treatment
Characteristics analyzed included clinical features, body
weight, blood pressure, and biochemical data, both before
treatment and within 3 months after initial treatment
(Table 2). Significant changes were observed in body
weight, BMI, serum cortisol and ACTH levels, white blood
cell count, and glucose levels. Blood pressure tended tohormone levels before treatment predict recurrence of Cushing’s
x.doi.org/10.1016/j.jfma.2016.08.008
Table 1 Clinical characteristics of patients in remission, patients with persistent CD, and patients with recurrent CD.
Remission Persistent Recurrent p
N 27 7 7
Follow-up time or time to persistence or recurrence (mo) 42.3 (3.2e203.1) 2.6 (0.4e7.0) 39.9 (12.7e131.9) d
Age (y) 34.1  15.0 37.7  13.8 29.9  11.4 0.6
Sex (M/F) 4/23 0/7 1/6 0.8
Diameter of pituitary tumor (mm) 6.6  3.8 6.8  3.0 6.4  2.4 >0.99
Body weight (kg)
Before treatment 66.9  19.5 70.0  19.5 61.4  19.0 0.7
At 3 mo after treatment 59.6  18.7 68.8  22.3 62.4  17.7 0.6
Weight loss 3 mo after treatment 4.4  3.4 1.6  5.6 0.2  4.3 0.1
BMI (kg/m2)
Before treatment 27.9  5.9 26.5  7.2 25.9  6.7 0.7
At 3 mo after treatment 26.2  4.9 25.6  7.9 26.0  6.5 >0.99
Decrease in BMI 3 mo after treatment 2.2  1.4 0.6  1.9 0.2  1.8* 0.03
Cortisol at 8 am (mg/dL)
Before treatment 26.6  11.6 23.5  9.4 30.3  10.7 0.5
After treatmenta 13.6  14.7 24.1  8.5 10.1  4.3 0.1
ACTH at 8 am (pg/mL)
Before treatment 47.5  29.1 50.1  23.4 65.8  22.9 0.3
After treatmenta 12.9  11.8 43.0  26.6* 17.8  10.4** <0.001
DHEAS before treatment (mmol/L) 6.1  4.3 10.2 13.3  2.0* 0.1
White blood cell count (K/mL)
Before treatment 10.00  3.30 9.74  2.45 9.12  2.04 0.8
After treatment 7.58  1.56 8.49  2.10 7.17  2.11 0.4
Plasma glucose (mg/dL)
Before treatment 112.5  55.9 102  27.1 97.6  23.5 0.8
After treatment 93.0  35.8 85.2  13.2 97.7  21.0 0.7
Initial treatment
TSS 27 7 7 d
Short-term complicationsa
DI 3 (11.1) 0 (0) 0 (0) >0.99
Hypopituitarism 21 (77.8) 5 (71.4) 4 (57.1) 0.6
Long-term complicationsb
DI 0 0 0 d
Hypopituitarism 5 (33.3) 2 (40) 2 (33.3) >0.99
Data are presented as n (%), mean  standard deviation, or median.
* p < 0.05 versus remission.
** p < 0.05 versus persistent.
ACTH Z adrenocorticotropic hormone; BMI Z body mass index; CDZ Cushing’s disease; DHEAS, dehydroepiandrosterone sulfate; DI,
diabetes insipidus, TSS Z transsphenoidal surgery.
a Within 3 months.
b Lasting > 3 months.
4 C.-H. Kuo et al.
+ MODELdecrease after treatment, although this change was not
statistically significant.Predictors of recurrent or persistent disease
We analyzed the relationship between clinical character-
istics and outcomes (Tables 1,3 and 4). Twenty-seven pa-
tients stayed in remission during follow-up. These patients
had a significantly greater decrease in BMI and lower de-
hydroepiandrosterone sulfate (DHEAS) levels before treat-
ment, compared with patients who had recurrent CD (both
p < 0.05). They also had significantly lower ACTH levels
within 3 months after initial treatment compared with pa-
tients who had persistent CD (p < 0.05; Table 1). However,
DHEAS levels were only measured in 37.0% of patients in thePlease cite this article in press as: Kuo C-H, et al., Adrenocorticotropic
disease, Journal of the Formosan Medical Association (2016), http://dremission group and in 21.4% of patients in the other
groups. Higher ACTH levels within 3 months after initial
treatment were related to a persistent disease [odds ratio
adjusted for age, 1.09; 95% confidence interval (CI):
1.02e1.16; p < 0.01; Table 3]. Higher ACTH levels before
treatment predicted disease recurrence during follow-up
(hazard ratio adjusted for age, 1.04; 95% CI: 1.00e1.07;
p < 0.05; Table 4). Mean diameters of the pituitary tumors
in three groups had no difference, and thus they were not
potential predictors for prognosis (Table 1).Discussion
This study highlighted the changes of clinical characteris-
tics and outcomes of CD after treatment. It demonstratedhormone levels before treatment predict recurrence of Cushing’s
x.doi.org/10.1016/j.jfma.2016.08.008
Table 2 Changes of characteristics within 3 months after
initial treatment.
Before
treatment
N Z 41
After treatment
N Z 41
p
Body weight (kg) 65.1  20.1 62.4  18.9 0.0036
BMI (kg/m2) 27.3  6.2 26.0  5.8 0.0009
Systolic blood
pressure
(mmHg)
137  24 135  20 0.7
Diastolic blood
pressure
(mmHg)
91  17 87  13 0.5
Serum cortisol at
8 am (mg/dL)
26.2  11.0 14.7  13.2 0.0001
Serum ACTH at
8 am (pg/mL)
49.7  28.6 19.1  18.7 <0.0001
White blood cell
count (K/mL)
9.86  3.27 7.66  1.81 0.0002
Plasma glucose
(mg/dL)
115.3  56.9 90.3  27.5 0.0042
Data are presented as mean  standard deviation.
ACTHZ adrenocorticotropic hormone; BMIZ body mass index.
Table 3 Odds ratio (95% confidence interval) for pre-
dictors of persistent CD.
Crude Adjusted model
Age (y) 1.02 (0.96e1.09) 0.98 (0.89e1.08)
Weight loss
3 mo after
treatment (kg)
0.92 (0.73e1.15) d
Decrease in BMI
3 mo after
treatment
(kg/m2)
0.71 (0.41e1.25) d
Cortisol at 8 am
before
treatment
(mg/dL)
0.97 (0.89e1.05) d
Cortisol at 8 am
after treatment
(mg/dL)
1.06 (0.99e1.13) d
ACTH at 8 am
before treatment
(pg/mL)
1.00 (0.97e1.03) d
ACTH at 8 am
after treatment
(pg/mL)
1.09 (1.02e1.16)* 1.09 (1.02e1.16)*
DHEAS before
treatment
(mmol/L)
1.15 (0.71e1.87) d
Patients with initial remission were used as the reference group
(odds ratio Z 1); * p < 0.01.
ACTHZ adrenocorticotropic hormone; BMIZ body mass index;
CDZ Cushing’s disease; DHEAS, dehydroepiandrosterone
sulfate.
Table 4 Hazard ratios (95% confidence interval) for pre-
dictors of recurrent CD.
Crude Adjusted model
Age (y) 0.97 (0.91e1.03) 0.96 (0.90e1.03)
Weight loss 3 mo
after treatment
0.88 (0.72e1.08) d
Decrease in BMI 3 mo
after treatment
0.77 (0.49e1.20) d
Cortisol at 8 am
before treatment
(mg/dL)
1.03 (0.96e1.11) d
Cortisol at 8 am
after treatment
(mg/dL)
0.99 (0.93e1.06) d
ACTH at 8 am
before treatment
(pg/mL)
1.03 (1.00e1.06)* 1.04 (1.00e1.07)*
ACTH at 8 am
after treatment
(pg/mL)
1.07 (0.98e1.16) d
DHEAS before
treatment
(mmol/L)
1.29 (0.80e2.09) d
Patients with remission were used as the reference group
(hazard ratio Z 1); * p < 0.05.
ACTHZ adrenocorticotropic hormone; BMIZ body mass index;
CD Z Cushing’s disease; DHEAS Z dehydroepiandrosterone
sulfate.
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Please cite this article in press as: Kuo C-H, et al., Adrenocorticotropic
disease, Journal of the Formosan Medical Association (2016), http://dthat patients in remission had a larger decrease in BMI after
treatment and lower DHEAS levels before treatment,
compared with the recurrent group. Higher ACTH levels
before treatment could predict CD recurrence during
follow-up.
In our study, 69.2% of the patients achieved long-term
remission. This result was higher than the 67.2% reported in
a study of 61 patients in England in 2001,8 but lower than
the 72% reported in a study of 80 patients in the United
Kingdom in 2012,7 and the 71.1% reported in a study of 346
patients in the United States in 2013.4 Clinical features and
comorbidities in our study were similar to those reported in
the aforementioned studies.4,7
In terms of diagnostic tests for CD, ACTH levels, cortisol
levels, or diurnal changes do not have 100% screening
sensitivity. Observation of all three of these factors is
crucial for accurate diagnosis. We suggest using 2 mg/dL of
cortisol as the cut-off point when an overnight dose of 1 mg
of dexamethasone is used for screening CS, because two
patients in our study had false negative results when we
used 5 mg/dL of cortisol as the cut-off point. In terms of
other dynamic studies, we suggest that suppressible
cortisol levels after 48 hours of low-dose DST or non-
suppressible cortisol levels after 48 hours of high-dose DST
cannot be used to rule out a CD diagnosis. A diagnosis of CD
requires the clinician’s careful observation and full alert-
ness, as well as the assistance of laboratory tests.
In our study, the initial remission rate after TSS alone
was 82.9%, which was similar to previous studies17e19;
however, the recurrence rate was much higher (20.6%) than
other studies. This may be due to the reducedhormone levels before treatment predict recurrence of Cushing’s
x.doi.org/10.1016/j.jfma.2016.08.008
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and permanent DI (0%) were also lower in our study. The
remission rate among patients who encountered recurrent
or persistent disease after the second round of TSS was
approximately 80%, a rate that compares favorably with
other management. In our experience, TSS (if feasible)
stands out as the first choice of treatment in the manage-
ment of recurrent or persistent CD.
Higher ACTH levels before treatment were found to be
related to recurrence of CD in this study. There were higher
mean ACTH levels before treatment in the recurrent group,
compared with the remission group. Higher ACTH levels
before treatment may indicate much larger tumor burden
and local aggressiveness, which increases the difficulty of
complete tumor resection. Thus, the recurrence rate in-
creases when there are potential residual tumors. Another
potential predictor for prognosis is ACTH levels after
treatment; though we did not find statistical significance in
Cox regression analyses. Lower ACTH levels after treatment
would indicate a more complete treatment of the ACTH-
secreting tumor or more destruction of the pituitary gland.
However, in our study, patients received a supplemental
dose of GC postoperatively when surgeons believed that
tumors were completely resected and adrenal insufficiency
would occur without GC supplementation. In our clinical
practice, the dosage and regimen of GC prescription varied
between different surgeons. GC supplementation affects
ACTH and cortisol levels and thus is a potential confounder
and may interfere with the analyses. It is important for
patients with potential adrenal insufficiency to receive this
treatment, and it should not be abandoned simply to
attempt to predict outcome. Further study design with a
fixed dosage of GC supplement or certified protocols of GC
withdrawal before blood sampling may help to clarify this
potential disease predictor.
Lower DHEAS levels before treatment were also shown
in the remission group, compared to the recurrent group
in this study. DHEAS is an adrenal androgen.1 Although an
additional cortical androgen-stimulating hormone other
than ACTH may exist, ACTH plays a role in stimulating the
adrenal cortex to secrete DHEAS.20,21 Therefore, higher
serum DHEAS levels may indicate higher levels of ACTH
secretion from pituitary tumors. This may be the reason
why DHEAS levels were higher in patients with persistent
or recurrent CD. Unlike ACTH, DHEAS levels remain the
same throughout the day.20 This means that DHEAS may
be a better marker than ACTH for prediction of CD
recurrence. A recent study showed that DHEAS levels,
along with ACTH and cortisol levels, decreased after TSS
in all patients with CD except in those with persistent
disease.22 Burkhardt et al22 have also suggested DHEAS
levels as a novel biomarker for CD. Although DHEAS levels
before treatment were found to be significantly higher in
patients with CD recurrence in our study, the number of
patients for whom DHEAS data was available was too small
to come to a definite conclusion. This is worthy of further
study.
In terms of body weight, patients with CS are known to
have increased central adiposity owing to the fact that GC
plays an essential role in regulating metabolism and body
composition.23,24 A study of 14 patients showed that nearly
all fat deposits, including visceral fat, fat in pelvic bonePlease cite this article in press as: Kuo C-H, et al., Adrenocorticotropic
disease, Journal of the Formosan Medical Association (2016), http://dmarrow, subcutaneous fat of the trunk and limbs, and total
fat, reduced after CD remission.25 After treatment, body
fat redistribution was associated with favorable cardiovas-
cular risk. However, most patients remained overweight or
obese even after remission.25 In our study, average BMI
decreased from 27.4 kg/m2 to 26.0 kg/m2 after treatment
of CD. Further, BMI significantly decreased in the remission
group, compared to the recurrent group (p Z 0.03).
Although the number of patients was not high enough to
reach a definite conclusion, the results indicated that BMI
could easily be applied in clinical practice and may be a
predictor of CD recurrence.
Many studies pointed out that serum cortisol levels after
surgery correlated well with long term remission; however,
we found that they were not good predictors for persistent
or recurrent disease in our study. Some investigators sug-
gested that delayed resolution of adrenal autonomy resul-
ted in persistent postoperation hypercortisolism, even after
successful pituitary adenoma resection.26e28 During further
follow-up, there was a gradual decrease in serum cortisol
levels in these disease-free patients. However, serum ACTH
has a shorter half-life than serum cortisol and would be
decreased soon after successful pituitary adenoma resec-
tion. If the serum ACTH level after surgery remained high,
we found that it was a better predictor for persistent CD.
Limitations of this study include the small sample size,
retrospective study design, the different postoperative GC
supplementation regimens and dosage, and the small per-
centage of patients for whom DHEAS levels were available.
Prospective and well-designed studies should be conducted
to verify our observations.
In conclusion, the accurate and timely diagnosis of CD
requires careful observation and high levels of alertness,
accompanied by laboratory and imaging studies. Patients in
CD remission had a larger decrease in BMI after treatment
and lower DHEAS levels before treatment. Higher ACTH
levels before treatment predicted recurrence of CD. These
are potential predictors of prognosis, and are simple and
practical for clinical usage.Acknowledgments
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